This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Gilbert's disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Gilbert's disease is a benign, mildly symptomatic, non- haemolytic, unconjugated hyperbilirubinaemia in the absence of liver disease (1).

  • it is a common cause of isolated raised unconjugated bilirubin (2)
  • total plasma bilirubin can be as high as 80 mumol/l and mild intermittent jaundice does occur
  • inheritance pattern is probably autosomal recessive (3)
  • has been estimated that some 10-15% of the Western population suffers from Gilbert's syndrome

The main abnormality is decreased bilirubin conjugating capacity (4)

  • bilirubin-uridinediphosphate-glucuronosyltransferase (UGT1A1) is the only enzyme involved in the conjugation of bilirubin
    • in patients with Gilbert's syndrome, hepatic glucuronidation by UGT1A1 is reduced to about 30% of normal (1)
  • although Gilbert’s syndrome does not lead to progressive liver damage it has attracted attention regarding the pharmacogenetics of drug metabolism
    • apart from being the only physiological UGT capable of bilirubin glucuronidation, UGT1A1 also catalyzes the glucuronidation of 2-hydroxy-estrone and estradiol, and a number of therapeutic drugs such as ethinylestradiol, gemfibrozil, metabolites of irinotecan, simvastatin and buprenorphine

It is at least twice as common in men than in women (5)

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.